PAVM PAVmed
- 2.1250
- +0.2050+10.68%
PAVmed News
Reported Late Monday, PAVmed Q1 2024 Adj EPS $(0.99) Beats $(1.67) Estimate, Sales $1.010M Miss $1.053M Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.67) by 40.72 percent. This is a 42.77 percent increase over losses of $(1.73) per s
Press Release: PAVmed Provides Business Update and First Quarter 2024 Financial Results
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting
10-Q: Quarterly report
Express News | Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
Express News | Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technol
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned ...
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
PAVmed Partners With Cancer Center to Advance Care
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage m
Lucid Diagnostics Partners With the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $26 From $30
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript
Analysis
Price Target
No Data
